The Manufacturers Life Insurance Company Has $77,000 Stock Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

The Manufacturers Life Insurance Company lowered its position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 30.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,325 shares of the company’s stock after selling 10,864 shares during the period. The Manufacturers Life Insurance Company’s holdings in RAPT Therapeutics were worth $77,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. AQR Capital Management LLC acquired a new position in RAPT Therapeutics in the second quarter valued at about $270,000. Squarepoint Ops LLC bought a new position in shares of RAPT Therapeutics during the 2nd quarter valued at about $329,000. Cubist Systematic Strategies LLC lifted its holdings in shares of RAPT Therapeutics by 826.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 295,241 shares of the company’s stock valued at $900,000 after purchasing an additional 263,372 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of RAPT Therapeutics in the 2nd quarter valued at approximately $108,000. Finally, Renaissance Technologies LLC increased its stake in RAPT Therapeutics by 108.1% during the 2nd quarter. Renaissance Technologies LLC now owns 203,900 shares of the company’s stock worth $622,000 after purchasing an additional 105,900 shares in the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on RAPT. UBS Group cut their price target on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research note on Monday, September 9th. HC Wainwright reaffirmed a “neutral” rating on shares of RAPT Therapeutics in a research report on Tuesday, August 20th. Nine equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $18.17.

RAPT Therapeutics Stock Up 5.9 %

NASDAQ RAPT opened at $1.79 on Monday. The firm’s 50 day moving average is $2.02 and its 200-day moving average is $3.79. The company has a market capitalization of $62.47 million, a PE ratio of -0.57 and a beta of 0.33. RAPT Therapeutics, Inc. has a 12-month low of $1.66 and a 12-month high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.03. As a group, sell-side analysts expect that RAPT Therapeutics, Inc. will post -2.73 EPS for the current year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.